Tempus AI Shares Approach 1-Year Low as Cathie Wood’s ARK Increases Holdings While Selling Nvidia, Meta, and Other Tech Stocks
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 4 days ago
0mins
Should l Buy TEM?
Source: stocktwits
ARK Investment Management's Activity: ARK Investment Management has purchased more shares of Tempus this week, investing nearly $28 million in the company despite its stock hitting a one-year low. The firm has also reduced its stakes in several large tech holdings.
Tempus' Recent Developments: Tempus has expanded its role in precision oncology research and clinical trial optimization, partnering with major pharmaceutical companies like Daiichi Sankyo to develop new cancer therapies using AI technology.
Market Sentiment and Stock Performance: Despite a recent decline in Tempus' stock, analysts maintain a positive outlook, with several firms reiterating 'buy' ratings and projecting significant revenue growth for the company in the coming years.
Retail Investor Sentiment: Retail sentiment towards Tempus has shifted to a more cautious stance, with some investors expressing optimism about future growth opportunities, while the stock has seen a significant decline over the past year.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy TEM?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on TEM
Wall Street analysts forecast TEM stock price to rise
9 Analyst Rating
4 Buy
5 Hold
0 Sell
Moderate Buy
Current: 42.620
Low
76.00
Averages
84.38
High
105.00
Current: 42.620
Low
76.00
Averages
84.38
High
105.00
About TEM
Tempus AI, Inc. is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. It offers AI-enabled precision medicine solutions to physicians to deliver personalized patient care and, in parallel, facilitates discovery, development and delivery of optimal therapeutics. It provides three product lines: Genomics, Data and artificial intelligence applications (AI). The Genomics product line leverages its laboratories to provide next generation sequencing (NGS) diagnostics, polymerase chain reaction, profiling, molecular genotyping and other anatomic and molecular pathology testing. The data generated in its lab or ingested into its platform is structured and de-identified, prior to commercialization. Its AI Applications is focused on developing and providing diagnostics that are algorithmic in nature, implementing new software as a medical device, and building and deploying clinical decision support tools.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Cathie Wood Shifts AI Investment Focus to Healthcare
- Portfolio Rebalancing: Cathie Wood's aggressive shift from mega-cap tech and semiconductor stocks to increasing her stake in Tempus AI reflects her strong conviction in AI innovation within healthcare, particularly in disease detection and drug development.
- Market Trend Insight: As AI infrastructure becomes crowded and capital-intensive, ARK Invest's strategic pivot towards application-driven intelligence indicates that healthcare is poised to be the next significant frontier for AI value creation, especially in the transformation of precision medicine.
- Clinical Data Utilization: Tempus AI leverages vast clinical and genomic datasets to drive AI-powered diagnostics and treatment recommendations, and despite its shares declining over 20% year-to-date, ARK's continued buying demonstrates unwavering confidence in its long-term potential.
- Industry Structural Shift: The pharmaceutical sector is expected to face a patent cliff in the next five years, creating opportunities for AI-native platforms to accelerate drug discovery and optimize clinical trials, with emerging players like Totaligent enhancing their biologics-driven data capabilities through strategic acquisitions.
See More
Cathie Wood's ARK Divests Meta Shares to Invest in This AI Stock.
- ARK Invest's Stock Move: Cathie Wood's ARK Invest sold its shares in Meta on a significant day for the company.
- New Investment Focus: The firm redirected its investment towards Tempus AI, a healthcare technology company specializing in artificial intelligence.
See More
TEMPUS AI STOCK RISES 2% IN PREMARKET TRADING FOLLOWING COLLABORATION WITH DAIICHI SANKYO ON CANCER TREATMENT
Market Reaction: Tempus AI shares increased by 2% in pre-market trading.
Partnership Announcement: The rise in shares follows a partnership with Daiichi Sankyo focused on cancer drug development.
See More
The Future of Drug Discovery Driven by AI
- Efficiency in Drug Discovery: Recursion Pharmaceuticals has revolutionized drug development by synthesizing an average of 330 compounds in just 17 months, compared to the industry average of 2,500 compounds over 42 months, indicating a significant potential to disrupt traditional pharmaceutical processes.
- Substantial Partnership Revenue: With over $500 million in cumulative milestone payments and its first clinical proof-of-concept demonstrating the efficacy of AI-discovered molecules in real patients, Recursion showcases a promising commercial outlook that could lead to profitability in the future.
- Market Growth of Tempus AI: Tempus AI has achieved trailing revenue of $1.27 billion, growing approximately 30% annually, and its unique clinical data relationships make it nearly impossible for competitors to replicate, solidifying its leadership in precision medicine.
- Future Growth Potential: Analysts project nearly 30% annual revenue growth for Tempus AI over the next three years, with consensus price targets suggesting over 60% upside for the stock in the next year, highlighting its critical role in the transformation of the healthcare industry.
See More
Analysis of ARKK ETF's 52-Week Price Fluctuations
- Price Range Analysis: ARKK ETF's 52-week low is $38.5686 per share and high is $92.65, with the latest trade at $69.69, indicating significant volatility over the past year that could influence investor decisions and market sentiment.
- Technical Analysis Tool: Comparing the current share price to the 200-day moving average provides valuable insights for investors, helping them assess market trends and potential buy or sell opportunities.
- ETF Trading Mechanism: Exchange-traded funds (ETFs) trade like stocks, where investors buy and sell 'units' that can be created or destroyed based on demand, impacting the fund's liquidity and market performance.
- Inflows and Outflows Monitoring: Weekly monitoring of changes in shares outstanding helps identify notable inflows (new units created) or outflows (old units destroyed), which can affect the individual components held within ETFs and subsequently influence overall market performance.
See More
Tempus AI Shares Rise as Analyst Reiterates Buy Rating
- Analyst Rating Reiteration: Needham analyst Ryan MacDonald reiterated a Buy rating on Tempus AI with a $75 price target, reflecting confidence in the company's growth potential and likely attracting more investor interest.
- Research Findings Published: Tempus announced a new study in JCO Precision Oncology that highlights the value of advanced genomic profiling tools in identifying clinically actionable findings in community oncology, potentially solidifying the company's leadership in precision medicine.
- Actionable Findings Ratio: The study revealed that approximately 12% of patients in the pilot and expanded cohorts had potentially actionable findings linked to approved therapies identified solely through advanced testing features, indicating the effectiveness of the company's technology and market demand.
- Stock Price Volatility Trend: Despite Tempus AI's stock experiencing fluctuations from $37.23 to $103.25 over the past year, it currently trades at $52.85, remaining below its 20-day, 50-day, and 200-day moving averages, signaling ongoing downside pressure.
See More
Cathie Wood Shifts AI Investment Focus to Healthcare
- Portfolio Rebalancing: Cathie Wood's aggressive shift from mega-cap tech and semiconductor stocks to increasing her stake in Tempus AI reflects her strong conviction in AI innovation within healthcare, particularly in disease detection and drug development.
- Market Trend Insight: As AI infrastructure becomes crowded and capital-intensive, ARK Invest's strategic pivot towards application-driven intelligence indicates that healthcare is poised to be the next significant frontier for AI value creation, especially in the transformation of precision medicine.
- Clinical Data Utilization: Tempus AI leverages vast clinical and genomic datasets to drive AI-powered diagnostics and treatment recommendations, and despite its shares declining over 20% year-to-date, ARK's continued buying demonstrates unwavering confidence in its long-term potential.
- Industry Structural Shift: The pharmaceutical sector is expected to face a patent cliff in the next five years, creating opportunities for AI-native platforms to accelerate drug discovery and optimize clinical trials, with emerging players like Totaligent enhancing their biologics-driven data capabilities through strategic acquisitions.
See More
Cathie Wood's ARK Divests Meta Shares to Invest in This AI Stock.
- ARK Invest's Stock Move: Cathie Wood's ARK Invest sold its shares in Meta on a significant day for the company.
- New Investment Focus: The firm redirected its investment towards Tempus AI, a healthcare technology company specializing in artificial intelligence.
See More
TEMPUS AI STOCK RISES 2% IN PREMARKET TRADING FOLLOWING COLLABORATION WITH DAIICHI SANKYO ON CANCER TREATMENT
Market Reaction: Tempus AI shares increased by 2% in pre-market trading.
Partnership Announcement: The rise in shares follows a partnership with Daiichi Sankyo focused on cancer drug development.
See More
The Future of Drug Discovery Driven by AI
- Efficiency in Drug Discovery: Recursion Pharmaceuticals has revolutionized drug development by synthesizing an average of 330 compounds in just 17 months, compared to the industry average of 2,500 compounds over 42 months, indicating a significant potential to disrupt traditional pharmaceutical processes.
- Substantial Partnership Revenue: With over $500 million in cumulative milestone payments and its first clinical proof-of-concept demonstrating the efficacy of AI-discovered molecules in real patients, Recursion showcases a promising commercial outlook that could lead to profitability in the future.
- Market Growth of Tempus AI: Tempus AI has achieved trailing revenue of $1.27 billion, growing approximately 30% annually, and its unique clinical data relationships make it nearly impossible for competitors to replicate, solidifying its leadership in precision medicine.
- Future Growth Potential: Analysts project nearly 30% annual revenue growth for Tempus AI over the next three years, with consensus price targets suggesting over 60% upside for the stock in the next year, highlighting its critical role in the transformation of the healthcare industry.
See More
Analysis of ARKK ETF's 52-Week Price Fluctuations
- Price Range Analysis: ARKK ETF's 52-week low is $38.5686 per share and high is $92.65, with the latest trade at $69.69, indicating significant volatility over the past year that could influence investor decisions and market sentiment.
- Technical Analysis Tool: Comparing the current share price to the 200-day moving average provides valuable insights for investors, helping them assess market trends and potential buy or sell opportunities.
- ETF Trading Mechanism: Exchange-traded funds (ETFs) trade like stocks, where investors buy and sell 'units' that can be created or destroyed based on demand, impacting the fund's liquidity and market performance.
- Inflows and Outflows Monitoring: Weekly monitoring of changes in shares outstanding helps identify notable inflows (new units created) or outflows (old units destroyed), which can affect the individual components held within ETFs and subsequently influence overall market performance.
See More
Tempus AI Shares Rise as Analyst Reiterates Buy Rating
- Analyst Rating Reiteration: Needham analyst Ryan MacDonald reiterated a Buy rating on Tempus AI with a $75 price target, reflecting confidence in the company's growth potential and likely attracting more investor interest.
- Research Findings Published: Tempus announced a new study in JCO Precision Oncology that highlights the value of advanced genomic profiling tools in identifying clinically actionable findings in community oncology, potentially solidifying the company's leadership in precision medicine.
- Actionable Findings Ratio: The study revealed that approximately 12% of patients in the pilot and expanded cohorts had potentially actionable findings linked to approved therapies identified solely through advanced testing features, indicating the effectiveness of the company's technology and market demand.
- Stock Price Volatility Trend: Despite Tempus AI's stock experiencing fluctuations from $37.23 to $103.25 over the past year, it currently trades at $52.85, remaining below its 20-day, 50-day, and 200-day moving averages, signaling ongoing downside pressure.
See More
